Asset Details
Do you wish to reserve the book?
Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis
Do you wish to request the book?
Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis
2008
Overview
Background
Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients with peritoneal carcinomatosis. This prospective non-randomized study was designed to identify factors associated with postoperative morbidity and survival after peritonectomy HIPEC in patients with this condition.
Method
Data were prospectively collected from all patients with peritoneal carcinomatosis treated by means of peritonectomy and HIPEC at Uppsala University Hospital between October 2003 and September 2006. Depending on the primary tumor, mitomycin C or a platinum compound was used as a chemotherapeutic agent for perfusion.
Results
A total of 103 patients were treated. Primary tumors were pseudomyxoma peritonei (47 patients), colorectal cancer (38 patients), gastric cancer (6 patients), ovarian cancer (6 patients) and mesothelioma (5 patients). Postoperative morbidity was 56.3% and was significantly lower in patients treated with mitomycin C for pseudomyxoma peritonei (42%) than in those with another diagnosis treated with platinum compound (71%,
P
< 0.05). Postoperative mortality was less than 1%. At 2 years, overall survival was estimated to be 72.3%, and disease-free survival was 33.5%. Factors influencing overall and disease-free survival were tumor type and optimal cytoreduction.
Conclusion
Postoperative morbidity is dependent mainly on a tumor type; however, the chemotherapeutic agent used might also influence morbidity. Survival is determined by optimal cytoreduction and tumor type. Irrespective of age, patients with good performance status benefit from this treatment.
Publisher
Springer-Verlag,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Antineoplastic Agents - administration & dosage
/ Chemotherapy, Cancer, Regional Perfusion
/ Humans
/ MEDICIN
/ MEDICINE
/ Mitomycin - administration & dosage
/ Oncology
/ Peritoneal Neoplasms - drug therapy
/ Peritoneal Neoplasms - mortality
/ Peritoneal Neoplasms - surgery
/ Peritoneal Neoplasms/drug therapy/mortality/surgery
/ Platinum Compounds - administration & dosage
/ Surgery
/ Sweden
